🇺🇸 FDA
Pipeline program

VEGF Trap-Eye 2.0mg

VGFT-OD-0819

Phase 3 mab completed

Quick answer

VEGF Trap-Eye 2.0mg for Macular Edema Secondary to Central Retinal Vein Occlusion is a Phase 3 program (mab) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Regeneron UK Limited
Indication
Macular Edema Secondary to Central Retinal Vein Occlusion
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials